Financial Times Healthcare
Blow to Ark Therapeutics
Ark Therapeutics was among the biggest small-cap fallers yesterday. Its shares dropped 11.1 per cent to 11½p after the biotechnology company said it had...
Sanofi joins Merck in animal health venture
Sanofi-Aventis of France yesterday paid $1bn to Merck of the US as part of a deal to establish a joint venture which will be the world's largest animal health...
Insurers plan ads blitz on health reform
The US Chamber of Commerce and the insurance industry are to mount a final offensive in their fight against healthcare reform with a multi-million dollar advertising...
Sanofi joins Merck in animal health venture
The pharmaceutical group has agreed a deal to establish a joint venture with Merck which will be the world's largest animal health business
Bupa's Asia growth mitigates UK, US slowness
Strong growth in customer numbers in Asia and the acquisition of MBF, the Australian insurer, helps mitigate sluggish performance of the medical insurance group in the US and UK
Sanofi and Merck to combine animal divisions
French and US pharmaceutical groups agree to join their animal health operations, creating a joint venture with nearly $5.3bn in annual sales
Regulator finds ethics breach by AstraZeneca
AstraZeneca failed to reflect accurately the side-effects of its top-selling anti-psychotic drug, Seroquel, in an advertisement to doctors, a UK regulatory panel has...
Intertek buoyed by increase in product testing
Ongoing product recalls, such as those by Toyota of more than 8m cars, are likely to spur companies to outsource further testing to third parties, the chief executive...
AstraZeneca job cuts reflect new landscape for drug innovation
When AstraZeneca revealed details last week of 3,500 job cuts across its global research and development operations, it was not just the company's own employees who...
Healthcare insurers forced to drop deal
The Obama administration dealt another blow to the insurance industry yesterday after it forced two Michigan companies to abandon plans for a deal because of antitrust...
Regulator finds ethics breach by AstraZeneca
A UK regulatory panel says the pharmaceutical group failed to accurately reflect the side effects of its top-selling antipsychotic drug Seroquel in an advertisement to doctors
AstraZeneca job cuts reflect new landscape
Anglo-Swedish pharmaceuticals group's move is latest in series of shake-ups that will have a key impact on the volume of medical innovation
Scottish start-up in £70m Sinopharm deal
Under the partnership agreement, the Chinese pharmaceutical distributor will undertake the regulatory compliance process in Beijing for Burdica Biomed's range of personal lubricants
3i buys majority stake in health chain
The UK's oldest private equity firm feels it has recovered sufficiently from the financial crisis to return to the dealmaking fray
Drug groups cautious on health changes
The pharmaceutical industry, which for months has been a crucial ally in the drive by Barack Obama, president, for US healthcare reform, is now taking a "wait-and-see"...
Public sector strike hits Portugal
Hospitals, schools and transport were severely disrupted in Portugal yesterday as public sector workers staged a 24-hour strike against a wage freeze and other...
New Silk Route smoothes the passage back into India
In a little-noticed deal that was sealed last week, New Silk Route, a New York-based growth capital firm, paid about $50m for a nearly 30 per cent interest in an...
Care UK goes private via Bridgepoint
The all-cash offer of 450p a share from private equity group Bridgepoint represents a premium and values the provider of nursing and elderly home care at £423m
Tiger sponsor stays true
Nike would continue its sponsorship of Tiger Woods because it was wedded to working with the best athletes to sell its products, brand president Charlie Denson told...
Omega board is fighting a losing battle with Invesco
Except on the principle that if you look after the pennies, the (billions) of pounds will look after themselves, it is hard to see why Neil Woodford should be...